Clinical applications of next-generation sequencing-based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression.
breast cancer
circulating tumor DNA
liquid biopsy
precision medicine
targeted therapies
therapeutic targets
Journal
Molecular oncology
ISSN: 1878-0261
Titre abrégé: Mol Oncol
Pays: United States
ID NLM: 101308230
Informations de publication
Date de publication:
12 Jun 2024
12 Jun 2024
Historique:
revised:
03
03
2024
received:
02
11
2023
accepted:
17
05
2024
medline:
13
6
2024
pubmed:
13
6
2024
entrez:
13
6
2024
Statut:
aheadofprint
Résumé
The advancements in the detection and characterization of circulating tumor DNA (ctDNA) have revolutionized precision medicine and are likely to transform standard clinical practice. The non-invasive nature of this approach allows for molecular profiling of the entire tumor entity, while also enabling real-time monitoring of the effectiveness of cancer therapies as well as the identification of resistance mechanisms to guide targeted therapy. Although the field of ctDNA studies offers a wide range of applications, including in early disease, in this review we mainly focus on the role of ctDNA in the dynamic molecular characterization of unresectable locally advanced and metastatic BC (mBC). Here, we provide clinical practice guidance for the rapidly evolving field of molecular profiling of mBC, outlining the current landscape of liquid biopsy applications and how to choose the right ctDNA assay. Additionally, we underline the importance of exploring the clinical relevance of novel molecular alterations that potentially represent therapeutic targets in mBC, along with mutations where targeted therapy is already approved. Finally, we present a potential roadmap for integrating ctDNA analysis into clinical practice.
Identifiants
pubmed: 38867388
doi: 10.1002/1878-0261.13671
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Astra Zeneca
Organisme : Menarini Silicon Biosystems
Organisme : Novartis
Informations de copyright
© 2024 The Author(s). Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
Références
Berger MF, Mardis ER. The emerging clinical relevance of genomics in cancer medicine. Nat Rev Clin Oncol. 2018;15(6):353–365.
Buono G, Gerratana L, Bulfoni M, Provinciali N, Basile D, Giuliano M, et al. Circulating tumor DNA analysis in breast cancer: is it ready for prime‐time? Cancer Treat Rev. 2019;73:73–83.
Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early‐ and late‐stage human malignancies. Sci Transl Med. 2014;6(224):224ra24.
Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. Lancet. 2021;397(10286):1750–1769.
Harbeck N, Gnant M. Breast cancer. Lancet. 2017;389(10074):1134–1150.
Saura C, Hlauschek D, Oliveira M, Zardavas D, Jallitsch‐Halper A, de la Peña L, et al. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor‐positive, HER2‐negative, early‐stage breast cancer (LORELEI): a multicentre, randomised, double‐blind, placebo‐controlled, phase 2 trial. Lancet Oncol. 2019;20(9):1226–1238.
Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long‐term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–172.
Burstein HJ, Curigliano G, Loibl S, Dubsky P, Gnant M, Poortmans P, et al. Estimating the benefits of therapy for early‐stage breast cancer: the St. Gallen international consensus guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019;30(10):1541–1557.
Heil J, Kuerer HM, Pfob A, Rauch G, Sinn HP, Golatta M, et al. Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges. Ann Oncol. 2020;31(1):61–71.
Zhou Q, Gampenrieder SP, Frantal S, Rinnerthaler G, Singer CF, Egle D, et al. Persistence of ctDNA in patients with breast cancer during Neoadjuvant treatment is a significant predictor of poor tumor response. Clin Cancer Res. 2021;28(4):697–707.
Marinovich ML, Houssami N, Macaskill P, von Minckwitz G, Blohmer J‐U, Irwig L. Accuracy of ultrasound for predicting pathologic response during neoadjuvant therapy for breast cancer. Int J Cancer. 2015;136(11):2730–2737.
Gampenrieder SP, Peer A, Weismann C, Meissnitzer M, Rinnerthaler G, Webhofer J, et al. Radiologic complete response (rCR) in contrast‐enhanced magnetic resonance imaging (CE‐MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence‐free survival but not pathologic complete response (pCR). Breast Cancer Res. 2019;21(1):19.
van Loevezijn AA, van der Noordaa MEM, van Werkhoven ED, Loo CE, Winter‐Warnars GAO, Wiersma T, et al. Minimally invasive complete response assessment of the breast after Neoadjuvant systemic therapy for early breast cancer (MICRA trial): interim analysis of a multicenter observational cohort study. Ann Surg Oncol. 2021;28(6):3243–3253.
Tasoulis MK, Lee H‐B, Yang W, Pope R, Krishnamurthy S, Kim S‐Y, et al. Accuracy of post–Neoadjuvant chemotherapy image‐guided breast biopsy to predict residual cancer. JAMA Surg. 2020;155(12):e204103.
Heil J, Pfob A, Sinn H‐P, Rauch G, Bach P, Thomas B, et al. Diagnosing pathologic complete response in the breast after Neoadjuvant systemic treatment of breast cancer patients by minimal invasive biopsy. Ann Surg. 2022;275(3):576–581.
Harbeck N, Penault‐Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, et al. Breast cancer. Nat Rev Dis Primers. 2019;5(1):66.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.
Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD‐3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population‐based registries in 71 countries. Lancet. 2018;391(10125):1023–1075.
Antonarelli G, Corti C, Tarantino P, Salimbeni BT, Zagami P, Marra A, et al. Management of patients with HER2‐positive metastatic breast cancer after trastuzumab deruxtecan failure. ESMO Open. 2023;8(4):101608.
Miglietta F, Bottosso M, Griguolo G, Dieci MV, Guarneri V. Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival. ESMO Open. 2022;7(2):100409.
Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–752.
Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98(19):10869–10874.
Sørlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100(14):8418–8423.
Balic M, Thomssen C, Gnant M, Harbeck N. St. Gallen/Vienna 2023: optimization of treatment for patients with primary breast cancer – a brief summary of the consensus discussion. Breast Care. 2023;18(3):213–222.
Perakis S, Speicher MR. Emerging concepts in liquid biopsies. BMC Med. 2017;15(1):75.
Byler S, Goldgar S, Heerboth S, Leary M, Housman G, Moulton K, et al. Genetic and epigenetic aspects of breast cancer progression and therapy. Anticancer Res. 2014;34(3):1071–1077.
Kim C, Lee J, Lee W, Kim A. Changes in intrinsic subtype of breast cancer during tumor progression in the same patient. Int J Clin Exp Pathol. 2015;8(11):15184–15190.
Sant M, Bernat‐Peguera A, Felip E, Margelí M. Role of ctDNA in breast cancer. Cancer. 2022;14(2):310.
Aftimos P, Oliveira M, Irrthum A, Fumagalli D, Sotiriou C, Gal‐Yam EN, et al. Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in AURORA, the breast international group (BIG) molecular screening initiative. Cancer Discov. 2021;11(11):2796–2811.
Kotecha R, Tonse R, Rubens M, McDermott MW, Odia Y, Appel H, et al. Systematic review and meta‐analysis of breast cancer brain metastasis and primary tumor receptor expression discordance. Neurooncol Adv. 2021;3(1):vdab010.
Priedigkeit N, Hartmaier RJ, Chen Y, Vareslija D, Basudan A, Watters RJ, et al. Intrinsic subtype switching and acquired ERBB2/HER2 amplifications and mutations in breast cancer brain metastases. JAMA Oncol. 2017;3(5):666–671.
Hulsbergen AFC, Claes A, Kavouridis VK, Ansaripour A, Nogarede C, Hughes ME, et al. Subtype switching in breast cancer brain metastases: a multicenter analysis. Neuro Oncol. 2020;22(8):1173–1181.
Klebe M, Fremd C, Kriegsmann M, Kriegsmann K, Albrecht T, Thewes V, et al. Frequent molecular subtype switching and gene expression alterations in lung and pleural metastasis from luminal A–type breast cancer. JCO Precis Oncol. 2020;4:848–859.
Russo M, Bardelli A. Lesion‐directed therapies and monitoring tumor evolution using liquid biopsies. Cold Spring Harb Perspect Med. 2017;7(2):a029587.
Pascual J, Attard G, Bidard F‐C, Curigliano G, Mattos‐Arruda LD, Diehn M, et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO precision medicine working group. Ann Oncol. 2022;33(8):750–768.
Jørgensen CLT, Larsson A‐M, Forsare C, Aaltonen K, Jansson S, Bradshaw R, et al. PAM50 intrinsic subtype profiles in primary and metastatic breast cancer show a significant shift toward more aggressive subtypes with prognostic implications. Cancer. 2021;13(7):1592.
Bertucci F, Ng CKY, Patsouris A, Droin N, Piscuoglio S, Carbuccia N, et al. Genomic characterization of metastatic breast cancers. Nature. 2019;569(7757):560–564.
Caballero C, Irrthum A, Goulioti T, Cameron D, Norton L, Piccart M. International research to address the challenges of metastatic breast cancer: the AURORA program (BIG 14‐01). NPJ Breast Cancer. 2023;9(1):42.
Lefebvre C, Bachelot T, Filleron T, Pedrero M, Campone M, Soria J‐C, et al. Mutational profile of metastatic breast cancers: a retrospective analysis. PLoS Med. 2016;13(12):e1002201.
Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, et al. The genomic landscape of endocrine‐resistant advanced breast cancers. Cancer Cell. 2018;34(3):427–438.e6.
Pearson A, Proszek P, Pascual J, Fribbens C, Shamsher MK, Kingston B, et al. Inactivating NF1 mutations are enriched in advanced breast cancer and contribute to endocrine therapy resistance. Clin Cancer Res. 2020;26(3):608–622.
Nagarajan S, Rao SV, Sutton J, Cheeseman D, Dunn S, Papachristou EK, et al. ARID1A influences HDAC1/BRD4 activity, intrinsic proliferative capacity and breast cancer treatment response. Nat Genet. 2020;52(2):187–197.
Xu G, Chhangawala S, Cocco E, Razavi P, Cai Y, Otto JE, et al. ARID1A determines luminal identity and therapeutic response in estrogen‐receptor‐positive breast cancer. Nat Genet. 2020;52(2):198–207.
Turner NC, Kingston B, Kilburn LS, Kernaghan S, Wardley AM, Macpherson IR, et al. Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. Lancet Oncol. 2020;21(10):1296–1308.
Belic J, Koch M, Ulz P, Auer M, Gerhalter T, Mohan S, et al. Rapid identification of plasma DNA samples with increased ctDNA levels by a modified FAST‐SeqS approach. Clin Chem. 2015;61(6):838–849.
Suppan C, Brcic I, Tiran V, Mueller HD, Posch F, Auer M, et al. Untargeted assessment of tumor fractions in plasma for monitoring and prognostication from metastatic breast cancer patients undergoing systemic treatment. Cancer. 2019;11(8):1171.
Dandachi N, Posch F, Graf R, Suppan C, Klocker EV, Müller HD, et al. Longitudinal tumor fraction trajectories predict risk of progression in metastatic HR+ breast cancer patients undergoing CDK4/6 treatment. Mol Oncol. 2020;15(9):2390–2400.
Dang DK, Park BH. Circulating tumor DNA: current challenges for clinical utility. J Clin Invest. 2022;132(12):e154941.
Heidrich I, Ačkar L, Mossahebi Mohammadi P, Pantel K. Liquid biopsies: potential and challenges. Int J Cancer. 2021;148(3):528–545.
Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic—implementation issues and future challenges. Nat Rev Clin Oncol. 2021;18(5):297–312.
Vlataki K, Antonouli S, Kalyvioti C, Lampri E, Kamina S, Mauri D, et al. Circulating tumor DNA in the Management of Early‐Stage Breast Cancer. Cells. 2023;12(12):1573.
Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch R‐D, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001;61(4):1659–1665.
Rostami A, Lambie M, Yu CW, Stambolic V, Waldron JN, Bratman SV. Senescence, necrosis, and apoptosis govern circulating cell‐free DNA release kinetics. Cell Rep. 2020;31(13):107830.
Sanz‐Garcia E, Zhao E, Bratman SV, Siu LL. Monitoring and adapting cancer treatment using circulating tumor DNA kinetics: current research, opportunities, and challenges. Sci Adv. 2022;8(4):eabi8618.
Stroun M, Lyautey J, Lederrey C, Olson‐Sand A, Anker P. About the possible origin and mechanism of circulating DNA. Clin Chim Acta. 2001;313(1–2):139–142.
Diaz LA, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014;32(6):579–586.
Udomruk S, Orrapin S, Pruksakorn D, Chaiyawat P. Size distribution of cell‐free DNA in oncology. Crit Rev Oncol Hematol. 2021;166:103455.
Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985–990.
Pessoa LS, Heringer M, Ferrer VP. ctDNA as a cancer biomarker: a broad overview. Crit Rev Oncol Hematol. 2020;155:103109.
Liu B, Hu Z, Ran J, Xie N, Tian C, Tang Y, et al. The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: novel prognostic indexes based on ctDNA. Breast. 2022;65:116–123.
Hasenleithner SO, Speicher MR. A clinician's handbook for using ctDNA throughout the patient journey. Mol Cancer. 2022;21:81.
Singh RR. Target enrichment approaches for next‐generation sequencing applications in oncology. Diagnostics. 2022;12(7):1539.
Bewicke‐Copley F, Arjun Kumar E, Palladino G, Korfi K, Wang J. Applications and analysis of targeted genomic sequencing in cancer studies. Comput Struct Biotechnol J. 2019;17:1348–1359.
Chen K, Shields MD, Chauhan PS, Ramirez RJ, Harris PK, Reimers MA, et al. Commercial ctDNA assays for minimal residual disease detection of solid tumors. Mol Diagn Ther. 2021;25(6):757–774.
Parsons HA, Rhoades J, Reed SC, Gydush G, Ram P, Exman P, et al. Sensitive detection of minimal residual disease in patients treated for early‐stage breast cancer. Clin Cancer Res. 2020;26(11):2556–2564.
Moding EJ, Nabet BY, Alizadeh AA, Diehn M. Detecting liquid remnants of solid tumors: circulating tumor DNA minimal residual disease. Cancer Discov. 2021;11(12):2968–2986.
Dong Q, Chen C, Hu Y, Zhang W, Yang X, Qi Y, et al. Clinical application of molecular residual disease detection by circulation tumor DNA in solid cancers and a comparison of technologies: review article. Cancer Biol Ther. 2023;24(1):2274123.
Newman AM, Bratman SV, To J, Wynne JF, Eclov NCW, Modlin LA, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014;20(5):548–554.
André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA‐mutated, hormone receptor–positive advanced breast cancer. N Engl J Med. 2019;380(20):1929–1940.
Parsons HA, Beaver JA, Cimino‐Mathews A, Ali SM, Axilbund J, Chu D, et al. Individualized molecular analyses guide efforts (IMAGE): a prospective study of molecular profiling of tissue and blood in metastatic triple‐negative breast cancer. Clin Cancer Res. 2017;23(2):379–386.
Bidard F‐C, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: results from the randomized phase III EMERALD trial. J Clin Oncol. 2022;40(28):3246–3256. https://doi.org/10.1200/JCO.22.00338
Turner NC, Swift C, Kilburn L, Fribbens C, Beaney M, Garcia‐Murillas I, et al. ESR1 mutations and overall survival on Fulvestrant versus Exemestane in advanced hormone receptor–positive breast cancer: a combined analysis of the phase III SoFEA and EFECT trials. Clin Cancer Res. 2020;26(19):5172–5177.
Liu MC, MacKay M, Kase M, Piwowarczyk A, Lo C, Schaeffer J, et al. Longitudinal shifts of solid tumor and liquid biopsy sequencing concordance in metastatic breast cancer. JCO Precis Oncol. 2022;6:e2100321. https://doi.org/10.1200/PO.21.00321
Gezer U, Bronkhorst AJ, Holdenrieder S. The clinical utility of droplet digital PCR for profiling circulating tumor DNA in breast cancer patients. Diagnostics. 2022;12(12):3042.
Lipsyc‐Sharf M, de Bruin EC, Santos K, McEwen R, Stetson D, Patel A, et al. Circulating tumor DNA and late recurrence in high‐risk hormone receptor–positive, human epidermal growth factor receptor 2–negative breast cancer. J Clin Oncol. 2022;40(22):2408–2419.
Magbanua MJM, Swigart LB, Ahmed Z, Sayaman RW, Renner D, Kalashnikova E, et al. Clinical significance and biology of circulating tumor DNA in high‐risk early‐stage HER2‐negative breast cancer receiving neoadjuvant chemotherapy. Cancer Cell. 2023;41(6):1091–1102.e4.
Tie J, Cohen JD, Lahouel K, Lo SN, Wang Y, Kosmider S, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med. 2022;386(24):2261–2272.
Lennon AM, Buchanan AH, Kinde I, Warren A, Honushefsky A, Cohain AT, et al. Feasibility of blood testing combined with PET‐CT to screen for cancer and guide intervention. Science. 2020;369(6499):eabb9601.
Wu D, Zhou G, Jin P, Zhu J, Li S, Wu Q, et al. Detection of colorectal cancer using a simplified SEPT9 gene methylation assay is a reliable method for opportunistic screening. J Mol Diagn. 2016;18(4):535–545.
Dietrich D, Kneip C, Raji O, Liloglou T, Seegebarth A, Schlegel T, et al. Performance evaluation of the DNA methylation biomarker SHOX2 for the aid in diagnosis of lung cancer based on the analysis of bronchial aspirates. Int J Oncol. 2012;40(3):825–832.
Nicholson BD, Oke J, Virdee PS, Harris DA, O'Doherty C, Park JE, et al. Multi‐cancer early detection test in symptomatic patients referred for cancer investigation in England and Wales (SYMPLIFY): a large‐scale, observational cohort study. Lancet Oncol. 2023;24(7):733–743.
Agassi R, Czeiger D, Shaked G, Avriel A, Sheynin J, Lavrenkov K, et al. Measurement of circulating cell‐free DNA levels by a simple fluorescent test in patients with breast cancer. Am J Clin Pathol. 2015;143(1):18–24.
Garcia‐Murillas I, Chopra N, Comino‐Méndez I, Beaney M, Tovey H, Cutts RJ, et al. Assessment of molecular relapse detection in early‐stage breast cancer. JAMA Oncol. 2019;5(10):1473–1478.
Rothé F, Silva MJ, Venet D, Campbell C, Bradburry I, Rouas G, et al. Circulating tumor DNA in HER2‐amplified breast cancer: a translational research substudy of the NeoALTTO phase III trial. Clin Cancer Res. 2019;25(12):3581–3588.
Riva F, Bidard F‐C, Houy A, Saliou A, Madic J, Rampanou A, et al. Patient‐specific circulating tumor DNA detection during Neoadjuvant chemotherapy in triple‐negative breast cancer. Clin Chem. 2017;63(3):691–699.
Butler TM, Boniface CT, Johnson‐Camacho K, Tabatabaei S, Melendez D, Kelley T, et al. Circulating tumor DNA dynamics using patient‐customized assays are associated with outcome in neoadjuvantly treated breast cancer. Cold Spring Harb Mol Case Stud. 2019;5(2):a003772.
Magbanua MJM, Swigart LB, Wu H‐T, Hirst GL, Yau C, Wolf DM, et al. Circulating tumor DNA in neoadjuvant‐treated breast cancer reflects response and survival. Ann Oncol. 2021;32(2):229–239.
Coombes RC, Page K, Salari R, Hastings RK, Armstrong A, Ahmed S, et al. Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence. Clin Cancer Res. 2019;25(14):4255–4263.
Olsson E, Winter C, George A, Chen Y, Howlin J, Tang ME, et al. Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. EMBO Mol Med. 2015;7(8):1034–1047.
Turner NC, Swift C, Jenkins B, Kilburn L, Coakley M, Beaney M, et al. Results of the c‐TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate‐ and high‐risk early‐stage triple‐negative breast cancer. Ann Oncol. 2023;34(2):200–211.
Janni W. Analysis of ctDNA for the detection of minimal residual disease (MRD) using a tissue‐free, multiomic assay in patients with early‐stage breast cancer. San Antonio Breast Cancer Symposium. 2023 Presented 06122023 (Abstract PS06‐06).
Fernandez SV, Tan YF, Rao S, Fittipaldi P, Sheriff F, Borghaei H, et al. Validation of a molecular diagnostic test for circulating tumor DNA by next‐gen sequencing. Int J Mol Sci. 2023;24(21):15779.
Chan A, Moy B, Mansi J, Ejlertsen B, Holmes FA, Chia S, et al. Final efficacy results of Neratinib in HER2‐positive hormone receptor‐positive early‐stage breast cancer from the phase III ExteNET trial. Clin Breast Cancer. 2021;21(1):80–91.e7.
Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone‐receptor–positive advanced breast cancer. N Engl J Med. 2012;366(6):520–529.
Gennari A, André F, Barrios CH, Cortés J, Azambuja E d, DeMichele A, et al. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32(12):1475–1495.
Ghosh M, Naik R, Lingaraju SM, Susheela SP, Patil S, Srinivasachar GK, et al. Landscape of clinically actionable mutations in breast cancer ‘A cohort study’. Transl Oncol. 2021;14(1):100877.
Cullinane C, Fleming C, O'Leary DP, Hassan F, Kelly L, O'Sullivan MJ, et al. Association of Circulating Tumor DNA with disease‐free survival in breast cancer. JAMA Netw Open. 2020;3(11):e2026921.
Prat A, Brasó‐Maristany F, Martínez‐Sáez O, Sanfeliu E, Xia Y, Bellet M, et al. Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer. Nat Commun. 2023;14(1):1157.
Burstein HJ, Somerfield MR, Barton DL, Dorris A, Fallowfield LJ, Jain D, et al. Endocrine treatment and targeted therapy for hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer: ASCO guideline update. J Clin Oncol. 2021;39(35):3959–3977.
Brett JO, Spring LM, Bardia A, Wander SA. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor‐positive breast cancer. Breast Cancer Res. 2021;23(1):85.
Carausu M, Bidard F‐C, Callens C, Melaabi S, Jeannot E, Pierga J‐Y, et al. ESR1 mutations: a new biomarker in breast cancer. Expert Rev Mol Diagn. 2019;19(7):599–611.
Page K, Martinson LJ, Fernandez‐Garcia D, Hills A, Gleason KLT, Gray MC, et al. Circulating tumor DNA profiling from breast cancer screening through to metastatic disease. JCO Precis Oncol. 2021;5:1768–1776.
Zundelevich A, Dadiani M, Kahana‐Edwin S, Itay A, Sella T, Gadot M, et al. ESR1 mutations are frequent in newly diagnosed metastatic and loco‐regional recurrence of endocrine‐treated breast cancer and carry worse prognosis. Breast Cancer Res. 2020;22(1):16.
O'Leary B, Hrebien S, Morden JP, Beaney M, Fribbens C, Huang X, et al. Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer. Nat Commun. 2018;9(1):896.
Bidard F‐C, Hardy‐Bessard A‐C, Dalenc F, Bachelot T, Pierga J‐Y, Rouge T d l M, et al. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA‐1): a randomised, open‐label, multicentre, phase 3 trial. Lancet Oncol. 2022;23(11):1367–1377.
Jeselsohn R, Yelensky R, Buchwalter G, Frampton G, Meric‐Bernstam F, Gonzalez‐Angulo AM, et al. Emergence of constitutively active estrogen receptor‐α mutations in pretreated advanced estrogen receptor–positive breast cancer. Clin Cancer Res. 2014;20(7):1757–1767.
Burstein HJ, DeMichele A, Somerfield MR, Henry NL. Testing for ESR1 mutations to guide therapy for hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer: ASCO guideline rapid recommendation update. J Clin Oncol. 2023;41(18):3423–3425.
Oliveira M, Pominchuk D, Nowecki Z, Hamilton E, Kulyaba Y, Andabekov T. Camizestrant, a next‐generation oral SERD, vs fulvestrant in post‐menopausal women with advanced ER‐positive HER2‐negative breast cancer: results of the randomized, multi‐dose phase 2 SERENA‐2 trial. San Antonio Breast Cancer Symposium. 2022 Presented 08122022 (Abstract GS3‐02).
Oliveira M, Pominchuk D, Hamilton EP, Kulyaba Y, Melkadze T, Neven P, et al. Clinical activity of camizestrant, a next‐generation SERD, versus fulvestrant in patients with a detectable ESR1 mutation: exploratory analysis of the SERENA‐2 phase 2 trial. J Clin Oncol. 2023;41(16_suppl):1066.
Turner N, Huang‐Bartlett C, Kalinsky K, Cristofanilli M, Bianchini G, Chia S, et al. Design of SERENA‐6, a phase III switching trial of camizestrant in ESR1‐mutant breast cancer during first‐line treatment. Future Oncol. 2023;19(8):559–573.
Goetz MP, Plourde P, Stover DG, Bagegni N, Vidal GA, Brufsky A, et al. Open‐label, randomized study of lasofoxifene (LAS) vs fulvestrant (Fulv) for women with locally advanced/metastatic ER+/HER2‐ breast cancer (mBC), an estrogen receptor 1 (ESR1) mutation, and disease progression on aromatase (AI) and cyclin‐dependent kinase 4/6 (CDK4/6i) inhibitors. Ann Oncol. 2022;33(suppl_7):S808–S869.
Damodaran S, Plourde PV, Moore HCF, Anderson IC, Portman DJ. Open‐label, phase 2, multicenter study of lasofoxifene (LAS) combined with abemaciclib (Abema) for treating pre‐ and postmenopausal women with locally advanced or metastatic ER+/HER2− breast cancer and an ESR1 mutation after progression on prior therapies. J Clin Oncol. 2022;40(16_suppl):1022.
Hartmaier RJ, Trabucco SE, Priedigkeit N, Chung JH, Parachoniak CA, Vanden Borre P, et al. Recurrent hyperactive ESR1 fusion proteins in endocrine therapy‐resistant breast cancer. Ann Oncol. 2018;29(4):872–880.
Gou X, Anurag M, Lei JT, Kim B‐J, Singh P, Seker S, et al. Transcriptional reprogramming differentiates active from inactive ESR1 fusions in endocrine therapy‐refractory metastatic breast cancer. Cancer Res. 2021;81(24):6259–6272.
Brett JO, Ritterhouse LL, Newman ET, Irwin KE, Dawson M, Ryan LY, et al. Clinical implications and treatment strategies for ESR1 fusions in hormone receptor‐positive metastatic breast cancer: a case series. Oncologist. 2023;28(2):172–179.
Sobhani N, Roviello G, Corona SP, Scaltriti M, Ianza A, Bortul M, et al. The prognostic value of PI3K mutational status in breast cancer: a meta‐analysis. J Cell Biochem. 2018;119(6):4287–4292.
Mosele F, Stefanovska B, Lusque A, Tran Dien A, Garberis I, Droin N, et al. Outcome and molecular landscape of patients with PIK3CA‐mutated metastatic breast cancer. Ann Oncol. 2020;31(3):377–386.
André F, Ciruelos EM, Juric D, Loibl S, Campone M, Mayer IA, et al. Alpelisib plus fulvestrant for PIK3CA‐mutated, hormone receptor‐positive, human epidermal growth factor receptor‐2–negative advanced breast cancer: final overall survival results from SOLAR‐1. Ann Oncol. 2021;32(2):208–217.
Rugo HS, Lerebours F, Ciruelos E, Drullinsky P, Ruiz‐Borrego M, Neven P, et al. Alpelisib plus fulvestrant in PIK3CA‐mutated, hormone receptor‐positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open‐label, non‐comparative study. Lancet Oncol. 2021;22(4):489–498.
Suppan C, Graf R, Jahn S, Zhou Q, Klocker EV, Bartsch R, et al. Sensitive and robust liquid biopsy‐based detection of PIK3CA mutations in hormone‐receptor‐positive metastatic breast cancer patients. Br J Cancer. 2022;126(3):456–463.
Basu A, Lambring CB. Akt isoforms: a family affair in breast cancer. Cancer. 2021;13(14):3445.
Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, et al. Capivasertib in hormone receptor–positive advanced breast cancer. N Engl J Med. 2023;388(22):2058–2070.
Turner N, Oliveira M, Howell SJ, Dalenc F, Cortés J, Gomez H, et al. Abstract GS3‐04: GS3‐04 Capivasertib and fulvestrant for patients with aromatase inhibitor‐resistant hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer: results from the phase III CAPItello‐291 trial. Cancer Res. 2023;83(5_Supplement):GS3‐04.
Jhaveri K, Eli LD, Wildiers H, Hurvitz SA, Guerrero‐Zotano A, Unni N, et al. Neratinib + fulvestrant + trastuzumab for HR‐positive, HER2‐negative, HER2‐mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial. Ann Oncol. 2023;34(10):885–898.
Loboda AP, Adonin LS, Zvereva SD, Guschin DY, Korneenko TV, Telegina AV, et al. BRCA mutations—the Achilles heel of breast, ovarian and other epithelial cancers. Int J Mol Sci. 2023;24(5):4982.
Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, et al. Adjuvant Olaparib for patients with BRCA1‐ or BRCA2‐mutated breast cancer. N Engl J Med. 2021;384(25):2394–2405.
Tung NM, Garber JE. BRCA1/2 testing: therapeutic implications for breast cancer management. Br J Cancer. 2018;119(2):141–152.
Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee K‐H, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379(8):753–763.
Robson M, Im S‐A, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523–533.
Tung NM, Robson ME, Ventz S, Santa‐Maria CA, Nanda R, Marcom PK, et al. TBCRC 048: phase II study of Olaparib for metastatic breast cancer and mutations in homologous recombination‐related genes. J Clin Oncol. 2020;38(36):4274–4282.
Kingston B, Cutts RJ, Bye H, Beaney M, Walsh‐Crestani G, Hrebien S, et al. Genomic profile of advanced breast cancer in circulating tumour DNA. Nat Commun. 2021;12(1):2423.
Marabelle A, Fakih M, Lopez J, Shah M, Shapira‐Frommer R, Nakagawa K, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open‐label, phase 2 KEYNOTE‐158 study. Lancet Oncol. 2020;21(10):1353–1365.
Emens LA, Molinero L, Adams S, Rugo HS, Schneeweiss A, Diéras V, et al. 296P tumour mutational burden and clinical outcomes with first‐line atezolizumab and nab‐paclitaxel in triple‐negative breast cancer: exploratory analysis of the phase III IMpassion130 trial. Ann Oncol. 2020;31:S360–S361.
Maio M, Ascierto PA, Manzyuk L, Motola‐Kuba D, Penel N, Cassier PA, et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE‐158 study. Ann Oncol. 2022;33(9):929–938.
Venetis K, Cursano G, Pescia C, D'Ercole M, Porta FM, Blanco MC, et al. Liquid biopsy: cell‐free DNA based analysis in breast cancer. J Liq Biopsy. 2023;1:100002.
Lockwood CM, Borsu L, Cankovic M, Earle JSL, Gocke CD, Hameed M, et al. Recommendations for cell‐free DNA assay validations: a joint consensus recommendation of the Association for Molecular Pathology and College of American pathologists. J Mol Diagn. 2023;25(12):876–897.
Stenzinger A, Cuffel B, Paracha N, Vail E, Garcia‐Foncillas J, Goodman C, et al. Supporting biomarker‐driven therapies in oncology: a genomic testing cost calculator. Oncologist. 2023;28(5):e242–e253.
Finan C, Gaulton A, Kruger FA, Lumbers RT, Shah T, Engmann J, et al. The druggable genome and support for target identification and validation in drug development. Sci Transl Med. 2017;9(383):eaag1166.
Balic M, Wimmer K, Suppan C, Silovski T, Brunner C. Expert discussion: ASCO 2022. Breast Care. 2022;17(4):430–436.
Dandachi N, Balic M. Deciphering the molecular landscape of metastatic lobular breast cancer. EBioMedicine. 2022;86:104385.
Paradiso A, Bravaccini S, Pronzato P. Biomarkers: which ones do we really need today? Breast Care. 2023;18(4):315–317.
Stejskal P, Goodarzi H, Srovnal J, Hajdúch M, van't Veer LJ, Magbanua MJM. Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance. Mol Cancer. 2023;22(1):15.
Santonja A, Cooper WN, Eldridge MD, Edwards PAW, Morris JA, Edwards AR, et al. Comparison of tumor‐informed and tumor‐naïve sequencing assays for ctDNA detection in breast cancer. EMBO Mol Med. 2023;15(6):e16505.
Hays P. Trends in precision oncology and precision medicine 2.0. Advancing healthcare through personalized medicine. Cham: Springer International Publishing; 2021. p. 419–480.